Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer.

@article{Gamelin2008IndividualFD,
  title={Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer.},
  author={Erick C. Gamelin and R{\'e}my Delva and Jacques Jacob and Yacine Merrouche and Jean-Luc Raoul and Denis Pezet and E. Danquechin Dorval and Gilles Piot and Alain Morel and Michèle Boisdron-Celle},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2008},
  volume={26 13},
  pages={
          2099-105
        }
}
PURPOSE A phase III, multicenter, randomized study compared conventional dosing of fluorouracil (FU) plus folinic acid with pharmacokinetically guided FU dose adjustment in terms of response, tolerability, and survival. PATIENTS AND METHODS Two hundred eight patients with measurable metastatic colorectal cancer were randomly assigned to one of two arms: arm A (104 patients; 96 assessable), in which the FU dose was calculated based on body-surface area; and arm B (104 patients; 90 assessable… 

Pharmacokinetic dose adjustment of 5-FU in modified FOLFOX7 plus bevacizumab for metastatic colorectal cancer in Japanese patients: a-JUST phase II clinical trial

TLDR
Pharmacokinetic dose adjustment of FU in mFOLFOX7 plus bevacizumab can optimize FU concentrations promptly and is safe in Japanese patients with mCRC.

Individual 5-Fluorouracil Dose Adjustment via Pharmacokinetic Monitoring Versus Conventional Body-Area-Surface Method: A Meta-Analysis

Background: Recent studies suggest that 5-fluorouracil (5-FU) dosing by use of pharmacokinetic (PK) parameters is superior to the traditional body surface area (BSA) method in colorectal cancer

A community-based multicenter trial of pharmacokinetically guided 5-fluorouracil dosing for personalized colorectal cancer therapy.

BACKGROUND Pharmacokinetically guided (PK-guided) versus body surface area-based 5-fluorouracil (5-FU) dosing results in higher response rates and better tolerability. A paucity of data exists on

Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC).

BACKGROUND Variable chemotherapy exposure may cause toxicity or lack of efficacy. This study was initiated to validate pharmacokinetically (PK)-guided paclitaxel dosing in patients with advanced

Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes.

TLDR
The data on pharmacokinetically guided dose adjustment of 5-FU is reviewed and the potential of this approach to advance therapeutic outcomes is discussed, as well as recent advances in testing based on liquid chromatography-mass spectroscopy and a nanoparticle antibody-based immunoassay for 5-fu may now allow for routine monitoring of5-FU in clinical practice.

Kinetically Guided Neoadjuvant Chemoradiotherapy Based on 5-Fluorouracil in Patients with Locally Advanced Rectal Cancer

TLDR
The cumulative AUC of 5-FU (total exposure to the drug) correlated with cumulative5-FU dose and residual disease and the pCR and residual tumour stage were evaluated using preoperative tumour downstaging in magnetic resonance, postoperative histopathological staging and tumour regression rate (residual disease).

Clinical Benefit of Therapeutic Drug Monitoring in Colorectal Cancer Patients Who Received Fluorouracil-Based Chemotherapy

TLDR
5-FU TDM significantly reduced the toxicity of chemotherapy and improved its efficacy and can be routinely used in 5-FU-based chemotherapy.

A correlation study of fluorouracil pharmacodynamics with clinical efficacy and toxicity

TLDR
There is no clear evidence that increased plasma levels or pharmacokinetic adjusted doses of 5-FU were related to better efficacy, however, toxicity might be closely associated with increased plasmaLevels of5-FU.
...

References

SHOWING 1-10 OF 29 REFERENCES

A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma.

  • B. ArdalanL. Chua L. Morrell
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1991
TLDR
It is suggested that short-term infusional therapy of 5-FU and LV in patients with advanced metastatic colorectal cancer generates acceptable toxicity, with equivalent or superior survivability in previously treated and untreated patients versus alternative methods of administration of the two agents.

A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study.

TLDR
Administration of 5-FU as a continuous infusion for protracted periods clearly improves the therapeutic index for this agent in patients with advanced colon cancer with respect to response rate and reduced toxicity.

Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.

  • A. de GramontJ. Bosset L. Bedenne
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1997
TLDR
The bimonthly regimen was more effective and less toxic than the monthly regimen and definitely increased the therapeutic ratio, however, there was no evidence of increased survival.

Relationship between fluorouracil systemic exposure and tumor response and patient survival.

  • G. MilanoM. Etienne F. Demard
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1994
TLDR
The AUC remains significant in a multivariate analysis including tumor stage, demonstrating that the greater the FU systemic exposure, the longer the survival.

Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer.

TLDR
The regimen of 5FU plus low-dose leucovorin has now been shown to offer a statistically significant survival advantage versus 5FU alone and versus5FU plus high-dose MTX, a regimen that had shown promise in earlier trials.

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

  • R. GoldbergD. Sargent S. Alberts
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
TLDR
The FOLFOX regimen of oxaliplatin and infused fluorouracil plus leucovorin was active and comparatively safe and should be considered as a standard therapy for patients with advanced colorectal cancer.

Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer.

  • E. VokesR. Mick M. Ratain
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1996
TLDR
L-PFL-IFN is active in stage IV head and neck cancer and is a significant predictor of toxicity, and in women, optimization of response outcome requires a higher 5-FU concentration.